Immunotherapy-Chemo cocktail shows promise for tough head and neck cancers
NCT ID NCT04862650
First seen Feb 15, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have not had prior systemic therapy for their advanced disease. The main goal is to see how many patients respond to treatment after 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (immunotherapy) plus paclitaxel and carboplatin (chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced head and neck cancer that has returned or spread.
What could go wrong
This is a small, early-phase trial (46 people) with no control group, so results may not apply broadly. Side effects from chemo and immunotherapy can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.